Pfizer's 1st-qtr 2006 sees $4.11B income, return to form after major year-ago charges
World drugs behemoth Pfizer says that, in first-quarter 2006, it saw earnings of $4.11 billion, or $0.56 per share, a massive increase on the like, year-ago period which was impacted by major charges, including the repatriation of overseas profits, that weakened net income to $301.0 million or $0.04 per share.
During the three-month period, sales continued the slow decline witnessed for the past few years (Marketletter January 30), dropping 3% to $12.66 billion.
Despite this, many of Pfizer's medicines achieved double-digit growth in the quarter. Notable among these was the heart drug Caduet (amlodipine and atorvastatin), up 147% to $77.0 million, while Zyvox (linezolid), a drug approved against a range of infections, grew 30% to $186.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze